Search All UT System Experts

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer

Lecia V. Sequist, Joachim Von Pawel, Edward G. Garmey, Wallace L. Akerley, Wolfram Brugger, Dora Ferrari, Yinpu Chen, Daniel B. Costa, David E. Gerber, Sergey Orlov, Rodryg Ramlau, Susan Arthur, Igor Gorbachevsky, Brian Schwartz, Joan H. Schiller

Research output: Contribution to journal › Article › peer-review

361 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences